CNTA
Centessa Pharmaceuticals plc (CNTA)
Healthcare • NASDAQ • $40.500.00%
- Symbol
- CNTA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $40.50
- Daily Change
- 0.00%
- Market Cap
- $6.19B
- Trailing P/E
- N/A
- Forward P/E
- -22.37
- 52W High
- $40.26
- 52W Low
- $12.39
- Analyst Target
- $44.17
- Dividend Yield
- N/A
- Beta
- 1.12
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United…
Company websiteResearch CNTA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.